Register for our free email digests:
David Wallace
Executive Editor
Generics Bulletin Managing Editor Dave Wallace has nearly 10 years experience of reporting on the global generic, biosimilar, value-added and OTC medicines industries. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Latest From David Wallace
CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
Mylan And Lupin Prepare To Launch EU Etanercept
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
Alvogen Group Unveils Adalvo B2B Unit
The Alvogen group of companies has unveiled Adalvo as the new identity for its B2B business unit. In an exclusive interview, general manager Anil Okay talks to Generics Bulletin about the reasons behind the rebranding, what makes it unique in the B2B sphere, and the significance of 2023 for Adalvo’s strategy.
CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
Meitheal Introduces US Enoxaparin
Meitheal has launched enoxaparin in the US following its FDA approval towards the end of last year.
Zentiva Opens India Office As It Completes Ankleshwar Plant Deal
Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.